Navigation Links
Sinovac to Participate in Two Upcoming Investor Conferences
Date:10/29/2008

BEIJING, Oct. 29 /Xinhua-PRNewswire/ -- Sinovac Biotech Ltd. (Amex: SVA), a vaccine-focused biotech company in China, announced today that it is scheduled to present at two upcoming investor conferences, including the Oppenheimer 19th Annual Healthcare Conference in New York City and the Credit Suisse Asian Healthcare Conference in Beijing, China.

Ms. Vanessa Wu, Senior Financial Manager, is scheduled to present on Tuesday, November 4, 2008 at 3:20 pm at Oppenheimer 19th Annual Healthcare Conference, at the Waldorf-Astoria Hotel in New York, NY.

Dr. Weidong Yin, Chairman, President and CEO, is scheduled to attend the Credit Suisse Asian Healthcare Conference on November 5 and 6, at The Westin Beijing Hotel at Financial Street in Beijing, China.

About Sinovac

Sinovac Biotech Ltd. is a China-based biopharmaceutical company that focuses on the research, development, manufacture and commercialization of vaccines that protect against human infectious diseases. Sinovac's commercialized vaccines include Healive(R) (hepatitis A), Bilive(R) (combined hepatitis A and B), Anflu(R) (influenza) and Panflu(TM) (H5N1). Sinovac is currently developing Universal Pandemic Influenza vaccine and Japanese encephalitis vaccine. Additional information about Sinovac is available on its website, http://www.sinovac.com . To be added to our distribution list, please email: info@sinovac.com.

Safe Harbor Statement

This announcement contains forward-looking statements. These statements are made under the "safe harbor" provisions of the U.S. Private Securities Litigation Reform Act of 1995. These forward-looking statements can be identified by words or phrases such as "will," "expects," "anticipates," "future," "intends," "plans," "believes," "estimates" and similar statements. Among other things, the business outlook and quotations from management in this press release contain forward-looking statements. Statements that are not historical facts, including statements about Sinovac's beliefs and expectations, are forward-looking statements. Forward-looking statements involve inherent risks and uncertainties. A number of important factors could cause actual results to differ materially from those contained in any forward- looking statement. Sinovac does not undertake any obligation to update any forward-looking statement, except as required under applicable law.

For more information, please contact:

Helen G. Yang

Sinovac Biotech Ltd.

Tel: +86-10-8289-0088 x9871

Fax: +86-10-6296-6910

Email: info@sinovac.com

Investors/Media:

Stephanie Carrington

The Ruth Group

Tel: +1-646-536-7017

Email: scarrington@theruthgroup.com

Janine McCargo

The Ruth Group

Tel: +1-646-536-7033

Email: jmccargo@theruthgroup.com


'/>"/>
SOURCE Sinovac Biotech Ltd.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Sinovacs Credit Rating Upgraded to AAZ, Second Highest Rating
2. Sinovac Biotech Holds 2007 Annual General Meeting
3. Sinovac to Present at the 2008 UBS Global Life Sciences Conference
4. Sinovac Initiates Clinical Trials for Inactivated Hepatitis A Vaccine in Ukraine
5. Sinovac Launches Seasonal Influenza Vaccine Anflu(R) for 2008-2009 Flu Season
6. Sinovac Adjourns Annual General Meeting
7. Sinovac to Present at the Susquehanna Financial Groups Second Annual Beijing Management Summit Conference
8. Sinovac Reports Record Second Quarter 2008 Unaudited Financial Results
9. Sinovac Biotech Ltd. Schedules 2007 Annual Meeting of Shareholders
10. Sinovac Receives Healive(R) and Bilive(R) Purchase Orders from Provincial CDCs for Earthquake Disaster Areas
11. Sinovac Receives RMB 20 Million Purchase Order for Healive from Chinas Ministry of Health to Vaccinate Earthquake Victims
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/16/2017)... OH (PRWEB) , ... August 16, 2017 , ... ... a beneficial microbe delivery system, announced it has secured $2M in funding from ... Queen City Angels, Carmen Innovations, and SVG Thrive Fund. With this investment, 3Bar ...
(Date:8/15/2017)... Aug. 15, 2017 After spending the past two years ... crowdsourced data collection, GeneFo now offers this platform to healthcare stakeholders ... amplifying support, adherence, and data collection vis a vis their members, ... the successful launch of this offer. ... GeneFo ...
(Date:8/15/2017)... ... August 15, 2017 , ... Any expert in stem cell research or ... for more than half a century. Despite their essential roles in human health ... known that molecular tags developed for this purpose also tag other, more abundant, non-stem ...
(Date:8/15/2017)... ... August 15, 2017 , ... ... cart. Now mobile responsive, the new website makes it easy to navigate through ... between. Users can now find detailed product information, educational industry content and visit ...
Breaking Biology Technology:
(Date:4/18/2017)... -- Socionext Inc., a global expert in SoC-based imaging and computing solutions, ... which features the company,s hybrid codec technology. A demonstration utilizing TeraFaces ... will be showcased during the upcoming Medtec Japan at Tokyo Big ... Las Vegas Convention Center April 24-27. ... Click here for an image of ...
(Date:4/13/2017)... India , April 13, 2017 According to ... Proofing, Identity Authentication, Identity Analytics, Identity Administration, and Authorization), Service, Authentication Type, ... MarketsandMarkets™, the IAM Market is expected to grow from USD 14.30 Billion ... Growth Rate (CAGR) of 17.3%. ... MarketsandMarkets ...
(Date:4/11/2017)... April 11, 2017 No two people ... at the New York University Tandon School of ... have found that partial similarities between prints are ... in mobile phones and other electronic devices can ... The vulnerability lies in the fact that fingerprint-based ...
Breaking Biology News(10 mins):